Who is Steve Cohen? I wonder if he would take 4 times guaranteed on his money in 6 months?
Could the EMA give a limited label .Are sales expected to be low for Arikace in the CF EU market.Could Arikayce fail the Phase3 trial? Could the label in the US be for only refractory (less than 10% of patients) , of course there will be no sales for CF.. No Billions!! LOL SLAM DUNK !!
Long and amused. Surfs up kids
FRAUD -ALERT- GOLDMAN SACHS DID NOT PUT THE MAIL STORY OUT TO THEIR INVESTORS - BIOWATCHDOG JDSOUZA ALAZONER CAMPFUND1 levinchico visionquest ARE ALL kvncmcdd
ps- Cathy said she had to repost my morning post 7 times... No wonder they call you the clowns
Get a life.
Its all about NTM. ...Many of us have long posted about Insmeds predicament of 2 indications of the same dosage and being non competitive on a large scale for CF. (EU)
Novartis has the pricing power pressure. Insmed remains all about NTM. The question we have is how will the EMA decide on the patient population. IF Arikace gets a complete label in the EU and the FDAs trial is successful, we wont care about the spam of CF! or Iplex! - NTM will be very profitable.
Long INSM but will ring the register before Billions soon! with positive news. Good Luck
Thanks to Cathy ... I assume only a few fools would believe something so ridiculous
"jad9000 • Feb 11, 2015 " So, 2016 would be a market of 17,500 at a price of around $50,000 annually or slightly under $900 million. All of the EU would be then be around 35,000 cases at $50,000 annually, or $1.75 billion. Then we add in CF, Japan with their 35,000 cases (40,000 by 2016) and the year after the US market around 35,000 (also 40,000 by 2016). That's quite a few billions of dollars by the end of 2016"
OTHAY! ok Ill stop but these fools hyping nonsense really should try and get DD from informed sources not these clowns
- Guess the date of the next dilution!
or partner.... Have more fun . Im long since 14.1. $0.70 and out DGLY
surfs up !
The 10 k states that Insmed will have no material revenues for at least 2 years . all those crzycht 800Million by 2016! jad9000 The 10k gives guidance to approval launch and market penetration
Insmed is on the biotech road , its a long one. Good Luck
That was stock options that were exercisable yesterday - 23.3 for Schaeffer, Orlov S Nicole Feb 27, 2015- 23.3 KB -Drechsler, Andrew T -Feb 27, 2015 -23.3 KB -Berry, Peggy Feb 27, 2015- 23.3 KB - Lewis, William Feb 27, 2015. 23.3
the postman always knocks twice. I have suggested all traders leave this bd. I do not post here.I am up 41% this year ... and the clowns who follow me incessantly know it . Long INSM from 14.1 ( but 4 short profitable trades) but INSM is pivoting . Poor kvn - he tries so hard LOL!! .........buh bye